Kyowa Kirin Co Ltd

Kyowa Kirin Co Ltd

Health CarePharmaceuticals and Biotechnology
  • Price (JPY)2,835.00
  • Today's Change21.00 / 0.75%
  • Shares traded165.10k
  • 1 Year change-5.66%
  • Beta0.6721
Data delayed at least 20 minutes, as of Mar 22 2023 01:18 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of pharmaceuticals and industrial raw materials mainly for amino acid and nucleic acid related substances, as well as healthcare products.

  • Revenue in JPY (TTM)398.37bn
  • Net income in JPY53.57bn
  • Incorporated1949
  • Employees5.98k
  • Location
    Kyowa Kirin Co LtdOtemachi Financial City Grand Cube1-9-2, Ote-machiCHIYODA-KU 100-0004JapanJPN
  • Phone+81 352057200
  • Fax+81 352057182
  • Websitehttps://www.kyowakirin.co.jp/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Hisamitsu Pharmaceutical Co Inc125.41bn12.96bn310.00bn2.78k22.411.0717.402.47162.40162.401,571.353,393.170.39142.883.5845,047,
Sumitomo Pharma Co Ltd588.23bn-8.45bn314.74bn6.99k--0.494820.930.5351-21.27-21.271,480.561,598.700.4411.943.8684,188,920.00-2.044.10-2.785.9769.5673.85-4.638.671.58--0.263521.778.546.520.345112.490.0529.24
Nippon Shinyaku Co., Ltd.141.11bn24.60bn410.97bn2.13k16.022.0113.962.91365.21365.212,095.122,905.010.64631.472.8166,405,650.0011.2710.1912.8912.0660.8657.6917.4415.324.07--0.010730.9812.826.8427.8716.2915.4918.04
Santen Pharmaceutical Co Ltd270.24bn-8.20bn420.46bn4.32k--1.3844.441.56-23.70-23.70691.02784.800.63612.942.8862,628,500.00-1.936.25-2.367.5658.4060.55-3.0310.302.23-0.63590.168843.856.675.99192.384.6030.424.24
TAISHO PHARMACEUTICAL HOLDINGS Co Ltd295.82bn25.05bn468.27bn9.13k18.020.56989.101.58305.13305.133,603.859,652.720.32462.644.5232,386,800.002.983.223.303.5660.1763.269.199.775.06--0.0034.17-4.89-0.8411-1.46-14.5410.26-1.89
Rohto Pharmaceutical Co Ltd231.89bn25.72bn606.74bn6.87k22.852.8218.012.62112.42112.421,013.50910.750.80392.514.0433,773,230.008.976.7712.469.5257.7659.2911.167.831.89--0.068521.6110.135.2525.5315.9923.2711.38
Kobayashi Pharmaceutical Co Ltd166.26bn20.02bn625.96bn3.45k30.883.0824.663.77259.70259.702,155.592,603.470.65414.513.23--7.888.079.8710.3655.5357.7112.0412.053.00--0.00431.467.091.181.564.7738.329.18
ONO PHARMACEUTICAL CO., LTD.428.95bn111.56bn1.43tn3.69k12.101.8711.043.33228.32228.32877.591,477.240.54622.543.79116,341,500.0014.249.4615.9110.8875.1373.0926.0721.023.48--0.012138.2216.848.106.757.61-12.606.96
Kyowa Kirin Co Ltd398.37bn53.57bn1.52tn5.98k28.241.9821.093.8199.6699.66741.061,419.270.4281.293.6766,594,950.005.765.896.526.6278.1875.2113.4514.574.29--0.028448.9813.092.432.344.545.1213.56
Shionogi & Co Ltd453.86bn200.91bn1.80tn5.69k8.701.638.273.97673.26673.261,513.623,585.510.39461.203.7179,722,110.0017.4313.3919.8515.0786.7582.4744.1735.364.75--0.00826.0312.77-0.22242.086.366.309.82
Eisai Co Ltd737.10bn26.71bn2.14tn11.32k77.622.6832.432.9193.1393.132,570.642,697.930.60961.783.6565,103,
Otsuka Holdings Co Ltd1.74tn134.02bn2.19tn33.23k15.880.95549.451.26246.77246.773,203.044,101.120.58682.824.33--4.644.775.675.8167.2367.377.918.641.80--0.07943.9316.006.996.823.566.810.00
Astellas Pharma Inc1.47tn136.43bn3.36tn14.52k24.482.1314.002.2974.8574.85803.18861.540.6031.813.56101,104,200.005.607.947.6510.9380.5978.899.2912.821.29--0.173347.163.73-0.23752.90-10.729.468.02
Data as of Mar 22 2023. Currency figures normalised to Kyowa Kirin Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

12.84%Per cent of shares held by top holders
HolderShares% Held
Nomura Asset Management Co., Ltd.as of 28 Feb 202317.32m3.21%
Daiwa Asset Management Co. Ltd.as of 28 Feb 20238.82m1.63%
Massachusetts Financial Services Co.as of 31 Jan 20238.63m1.60%
Nikko Asset Management Co., Ltd.as of 03 Mar 20238.53m1.58%
The Vanguard Group, Inc.as of 03 Mar 20236.62m1.23%
BlackRock Fund Advisorsas of 01 Mar 20235.21m0.96%
Mitsubishi UFJ Kokusai Asset Management Co., Ltd.as of 02 Mar 20234.50m0.83%
Norges Bank Investment Managementas of 31 Dec 20224.05m0.75%
Goldman Sachs Asset Management Co., Ltd. (Japan)as of 31 Dec 20223.00m0.56%
Goldman Sachs Asset Management Internationalas of 31 Oct 20222.65m0.49%
More ▼
Data from 31 Dec 2022 - 16 Mar 2023Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.